Investors
Press Releases
- 04/14/2008
Intelgenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion
- 04/07/2008
IntelGenx Corp. and Cary Pharmaceuticals Confirm Agreement to Develop a Novel Antidepressant
- 03/28/2008
IntelGenx Technologies Corp. announces closing of private placement
- 01/07/2008
IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million
- 11/21/2007
IntelGenx Technologies Corp. Reports Financial Results for the First Nine Months of 2007
- 11/05/2007
IntelGenx Corp. and Cary Pharmaceuticals Sign a Definitive Agreement to Develop a Novel Antidepressant
- 10/31/2007
IntelGenx Technologies Corp. Will Present Recent Achievements and Market Opportunities at Rodman & Renshaw’s 9th Annual Healthcare Conference, November 7, 2007
- 09/10/2007
IntelGenx Proprietary Delivery Technology Tested in Cannasat Therapeutics' Phase I Study for Drug Treatment for Neuropathic Pain
- 08/29/2007
IntelGenx Technologies Corp. Reports Revenues Increased by More Than 124% for the First Six Months of 2007
- 08/09/2007
IntelGenx Technologies Corp. Appoints New Chief Financial Officer
- 08/07/2007
Intelgenx Technologies Corp. Appoints New Vice President of Business Development
- 07/12/2007
IntelGenx Technologies Corp. Engages Consulting for Strategic Growth 1 for Investor and Public Relations
- 05/29/2007
Senior Executive Joins IntelGenx Technologies Corp. Management Team
- 05/24/2007
IntelGenx Technologies Corporation has completed the sale of secured convertible debentures in an aggregate principal amount of U.S. $1.5 million to certain institutional and accredited investors.
- 05/03/2007
IntelGenx Technologies Corporation and Cary Pharmaceuticals today announced that the pilot clinical trial of QuitPak showed positive intermediate results.
- 04/30/2007
IntelGenx Technologies Corporation today announced that the company signed a licensing and development agreement with a major US pharmaceutical company for the development and commercialization of a generic product.
- 03/26/2007
IntelGenx Technologies Corp. and Cary Pharmaceuticals Inc. announce enrollment of Phase I Pilot Study for QuitPak®
- 03/20/2007
Cannasat Therapeutics and IntelGenx enter into agreement to develop cannabinoid-based products for the treatment of mood disorders such as anxiety and depression
- 01/30/2007
IntelGenx Technologies Corp. enters into consulting agreement with Dr. David Coffin-Beach
- 01/05/2007
IntelGenx is developing two platform technologies; one is a Tri-Layer Tablet technology that allows for the development of oral controlled release products, and the second is a breakthrough Quick Release Wafer technology that is intended for the rapid delivery of pharmaceutically active substances
- 11/14/2006
Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery Technologies
- 4/28/06
Completed $1.35 million private placement
- 11/28/05
Entered into development agreement with Cary Pharmaceuticals